Publications Daniel Legler

  Publications in KOPS, the Institutional Repository of the Universität Konstanz


  • Jakobs BD, Spannagel L, Purvanov V, Uetz-von Allmen E, Matti C, Legler DF. 2019. Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7. Int J Mol Sci Int J Mol Sci. 2019 May 27;20(10). pii: E2597. doi: 10.3390/ijms20102597.
  • Impellizzieri D, Ridder F, Raeber ME, Egholm C, Woytschak J, Kolios AGA, Legler DF, Boyman O. 2019. IL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation. J Allergy Clin Immunol Feb 12. pii: S0091-6749(19)30203-9. doi: 10.1016/j.jaci.2019.01.042. [Epub ahead of print]
  • Laufer JM, Kindinger I, Artinger M, Pauli A, Legler DF. 2019. CCR7 Is Recruited to the Immunological Synapse, Acts as Co-stimulatory Molecule and Drives LFA-1 Clustering for Efficient T Cell Adhesion Through ZAP70. Front Immunol Jan 14;9:3115. doi: 10.3389/fimmu.2018.03115. eCollection 2018.
  • Purvanov V, Matti C, Samson GPB, Kindinger I, Legler DF. 2018. Fluorescently Tagged CCL19 and CCL21 to Monitor CCR7 and ACKR4 Functions. Int J Mol Sci Dec 4;19(12). pii: E3876. doi: 10.3390/ijms19123876.
  • Rossy J, Laufer JM, Legler DF. 2018. Role of Mechanotransduction and Tension in T Cell Function. Front. Immunol. 15 November 2018 | https://doi.org/10.3389/fimmu.2018.02638.
  • Jørgensen AS, Adogamhe PE, Laufer JM, Legler DF, Veldkamp CT, Rosenkilde MM, Hjortø GM. 2018. CCL19 with CCL21-tail displays enhanced glycosaminoglycan binding with retained chemotactic potency in dendritic cells. J Leukoc Biol Aug;104(2):401-411. doi: 10.1002/JLB.2VMA0118-008R.
  • Laufer JM, Legler DF. 2018. Beyond migration-Chemokines in lymphocyte priming, differentiation, and modulating effector functions. J Leukoc Biol Apr 18. doi: 10.1002/JLB.2MR1217-494R.
  • Uetz-von Allmen E, Rippl AV, Farhan H, Legler DF. 2018. A unique signal sequence of the chemokine receptor CCR7 promotes package into COPII vesicles for efficient receptor trafficking. J Leukoc Biol Mar 30. doi: 10.1002/JLB.2VMA1217-492R.
  • Laufer JM, Lyck R, Legler DF. 2018. ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins. FASEB J Mar 28. doi: 10.1096/fj.201701452RR.
  • Thelen M, Legler DF. 2018. Membrane lipid environment: Potential modulation of chemokine receptor function. Cytokine doi: 10.1016/j.cyto.2018.02.011.
  • Legler DF, Thelen M. 2018. New insights in chemokine signaling. F1000Res Jan 23;7:95. doi: 10.12688/f1000research.13130.1. eCollection 2018. Review.
  • Nyffeler J, Chovancova P, Dolde X, Holzer AK, Purvanov V, Kindinger I, Kerins A, Higton D, Silvester S, van Vugt-Lussenburg BMA, Glaab E, van der Burg B, Maclennan R, Legler DF, Leist M. 2018. A structure-activity relationship linking non-planar PCBs to functional deficits of neural crest cells: new roles for connexins. Arch Toxicol 92(3):1225-1247.
  • Collins PJ, McCully ML, Martínez-Muñoz L, Santiago C, Wheeldon J, Chaucheteux S, Thelen S, Cecchinato V, Laufer JM, Purvanov V, Monneau YR, Lortat-Jacob H, Legler DF, Uguccioni M, Thelen M, Piguet V, Mellado M, Moser B. 2017. Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4. FASEB J 31:3084-3097.
  • Legler DF, Matti C, Laufer JM, Jakobs BD, Purvanov V, Uetz-von Allmen E, Thelen M. 2017. Modulation of chemokine receptor function by cholesterol: new prospects for pharmacological intervention. Mol Pharmacol 91:331-338.
  • Legler DF, Thelen M. 2016. Chemokines: chemistry, biochemistry and biological function. Chimia 70:856-859.
  • Weitzenfeld P, Kossover O, Körner C, Meshel T, Wiemann S, Seliktar D, Legler DF, Ben-Baruch A. 2016. Chemokine axes in breast cancer: factors of the tumor microenvironment re-shape the CCR7-driven metastatic spread of luminal-A breast tumors. J Leuk Biol 99:1009-1025.
  • Hauser MA, Kindinger I, Laufer JM, Späte A-K, Bucher D, Vanes SL, Krueger WA, Wittmann V, Legler DF. 2016. Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic responses. J Leuk Biol 99:993-1007.
  • Hauser MA, Schaeuble K, Kindinger I, Impellizzieri D, Krueger WA, Hauck CR, Boyman O, Legler DF. 2016. Inflammation-Induced CCR7 Oligomers Form Scaffolds to Integrate Distinct Signaling Pathways for Efficient Cell Migration. Immunity Jan 19;44(1):59-72. doi: 10.1016/j.immuni.2015.12.010.
  • Hauser MA, Legler DF. 2016. Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes. J Leukoc Biol 99:869-892.
  • Herrmann VL, Wieland DE, Legler DF, Wittmann V, Groettrup M. 2016. The STEAP1262-270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-a new approach to immunotherapy against prostate carcinoma. Prostate 75:456-468.
  • Schachtner H, Weimershaus M, Stache V, Plewa N, Legler DF, Höpken UE, Maritzen T. 2015. Loss of Gadkin Affects Dendritic Cell Migration In Vitro. PLoS One Dec 1;10(12):e0143883. doi: 10.1371/journal.pone.0143883. eCollection 2015.
  • Ackerknecht M, Hauser MA, Legler DF, Stein JV. 2015. In vivo TCR Signaling in CD4(+) T Cells Imprints a Cell-Intrinsic, Transient Low-Motility Pattern Independent of Chemokine Receptor Expression Levels, or Microtubular Network, Integrin, and Protein Kinase C Activity. Front Immunol Jun 8;6:297. doi: 10.3389/fimmu.2015.00297. eCollection 2015.
  • Baschieri F, Uetz-von Allmen E, Legler DF, Farhan H. 2015. Loss of GM130 in breast cancer cells and its effects on cell migration, invasion and polarity. Cell Cycle 14:1139-1147.
  • Wu X, Wu J, Li H, Legler DF, Marshall AJ, Lin F. 2015. Analysis of CCR7 mediated T cell transfectant migration using a microfluidic gradient generator. J Immunol Methods 419:9-17.
  • Maritzen T, Schachtner H, Legler DF. 2015. On the move: Endocytic trafficking in cell migration. Cell Mol Life Sci 72(11):2119-2134.
  • Tillmann KD, Reiterer V, Baschieri F, Hoffmann J, Millarte V, Hauser MA, Mazza A, Atias N, Legler DF, Sharan R, Weiss M, Farhan H. 2015. Regulation of Sec16 levels and dynamics links proliferation and secretion. J Cell Sci 128(4):670-682.
  • Legler DF, Uetz-von Allmen E, Hauser MA. 2014. CCR7: Roles in cancer cell dissemination, migration and metastasis formation. Int J Biochem Cell Biol 54:78-82.
  • Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF, Luther SA, Bollenbach T, Sixt M. 2013. Interstitial dendritic cell guidance by haptotactic chemokine gradients.Science 339(6117):328-32.
  • Bruckner M, Dickel D, Singer E, Legler DF. 2012. Converse regulation of CCR7-driven human dendritic cell migration by prostaglandin E2 and liver X receptor activation.Eur J Immunol 42(11):2949-2958.
  • Schaeuble K, Hauser MA, Rippl AV, Bruderer R, Otero C, Groettrup M, Legler DF. 2012. Ubiquitylation of the chemokine receptor CCR7 enables efficient receptor recycling and cell migration.J Cell Sci 125(19):4463-4474.
  • Bruckner M, Dickel D, Singer E, Legler DF. 2012. Distinct modulation of chemokine expression pattern in human monocyte-derived dendritic cells by prostaglandin E2.Cell Immunol 276:52-58.
  • Schaeuble K, Hauser MA, Singer E, Groettrup M, Legler DF. 2011. Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol 187(11):5645-52.
  • Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF. 2010. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgenic mice. J Immunol 185:3445-3455.
  • Metzner C, Legler DF, Dangerfield JA. 2010. Surface engineering of biomembranes with glycosylphosphatidylinositol-anchored proteins and its applications. In GPI membrane anchors-the much needed link. Ed Dangerfield JA, Metzner C. Bentham e-book Chapter 6: 83-97. eISBN: 978-1-60805-123-6, 2010
  • Schumann K, Lämmermann T, Bruckner M, Legler DF, Polleux J, Spatz JP, Schuler G, Förster R, Lutz MB, Sorokin L, Sixt M. 2010. Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity 32(5):703-713.
  • Legler DF, Bruckner M, Uetz-von Allmen E, Krause P. 2010. Prostaglandin E(2) at new glance: Novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 42(2):198-201.
  • Boneberg EM, Illges H, Legler DF, Fürstenberger G. 2009. Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process. Microvasc Res 78(3):325-31.
  • Boneberg EM, Legler DF, Hoefer MM, Ohlschlegel C, Steininger H, Füzesi L, Beer GM, Dupont-Lampert V, Otto F, Senn HJ, Fürstenberger G. 2009. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer 101(4):605-614.
  • Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M, Legler DF. 2009. Prostaglandin E(2) enhances T cell proliferation by inducing the co-stimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 113(11):2451-2460.
  • Otero C, Eisele PS, Schaeuble K, Groettrup M, Legler DF. 2008. Distinct motifs of the chemokine receptor CCR7 regulate signal transduction, receptor trafficking, and chemotaxis. J Cell Sci 121:2759-2767.
  • Boneberg EM, Legler DF, Senn HJ, Fürstenberger G. 2008. Reduced expression of cyclooxygenase-2 in primary breast cancer. J Natl Cancer Inst 100:1042-1043.
  • Segura JM, Guillaume P, Mark S, Dojcinovic D, Johannsen A, Bosshard G, Angelov G, Legler DF, Vogel H, Luescher IF. 2008. Increased mobility of major histocompatibility complex I-peptide complexes decreases the sensitivity of antigen recognition. J Biol Chem 283:24254-24263.
  • Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. 2008. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27:6068-6074.
  • Uetz-von Allmen E, Koch M, Fritz G, Legler DF. 2008. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 68:748-758.
  • Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF. 2007. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leuk Biol 82(5):1106-1114.
  • Schlosser E, Otero C, Wünsch C, Kessler BM, Edelmann M, Brunisholz R, Drexler I, Legler DF*, Groettrup M*. 2007. A novel cytosolic class I antigen-processing pathway for endoplasmic-reticulum-targeted proteins. EMBO Rep 8:945-951. * share senior authorship
  • Otero C, Groettrup M, Legler DF. 2006. Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 177:2314-2323.
  • Langhorst MF, Reuter A, Luxenhofer G, Boneberg EM, Legler DF, Plattner H, Stuermer CAO. 2006. Preformed reggie/flotillin caps: stable priming platforms for macrodomain assembly in T cells. FASEB J 20:711-713, and FASEB J express article online
  • Nachbur U, Kassahn D, Yousefi S, Legler DF, Brunner T. 2006. Posttranscriptional regulation of Fas (CD95) ligand activity by lipid rafts. Blood 107:2790-2796.
  • Legler DF, Krause P, Scandella E, Singer E, Groettrup M. 2006. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176:966-973.
  • Legler DF, Doucey MA, Schneider P, Chapatte L, Bender FC, Bron C. 2005. Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. FASEB J 19:1-3, and FASEB J express article online
  • Stuermer CAO, Langhorst MF, Wiechers M, Legler DF, Hannbeck S, Guse AH, Plattner H. 2004. PrPc capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction. FASEB J 18:1731-1733, and FASEB J express article online
  • Legler DF, Johnson-Leger C, Wiedle G, Bron C, Imhof BA. 2004. The αvβ3 integrin as a tumor homing ligand for lymphocytes. EurJ Immunol 34:1608-1616.
  • Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, Ludewig B, Groettrup, M. 2004. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103:1595-1601.
  • Doucey MA, Legler DF, Faroudi M, Boucheron N, Baumgartner P, Naeher D, Cebecauer M, Hudrisier D, Ruegg C, Palmer E, Valitutti S, Bron C, Luescher IF. 2003. The β1 and β3 integrins promote T cell receptor-mediated cytotoxic T lymphocyte activation. J Biol Chem 278:26983-26991.
  • Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. 2003. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 18:655-664.
  • Guillaume P, Legler DF, Boucheron N, Doucey MA, Cerottini JC, Luescher IF. 2003. Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J Biol Chem 278:4500-4509.
  • Gaide O, Favier B, Legler DF, Bonnet D, Brissoni B, Valitutti S, Bron C, Tschopp J, Thome M. 2002. Carma1 is a critical lipid raft-associated regulator of TCR-induced NF-κB activation. Nat Immunol 3:836-843.
  • Rothenberger S, Rousseaux M, Knecht H, Bender FC, Legler DF, Bron C. 2002. Association of the Epstein-Barr virus Latent membrane protein 1 with lipid rafts is mediated through its N-terminal region. Cell Mol Life Sci 59:171-180.
  • Legler DF, Doucey MA, Cerottini JC, Bron C, Luescher IF. 2001. Selective inhibition of CTL activation by a dipalmitoyl-phospholipid that prevents the recruitment of signaling molecules to lipid rafts. FASEB J 15:1601-1603, and FASEB J express article online
  • Doucey MA, Legler DF, Boucheron N, Cerottini JC, Bron C, Luescher IF. 2001. CTL activation is induced by cross-linking of TCR/MHC-peptide - CD8/p56Lck adducts in rafts. Eur J Immunol 31:1561-1570.
  • Legler DF, Wiedle G, Ross FP, Imhof BA. 2001. Superactivation of integrin αvβ3 by low agonist concentrations. J Cell Sci 114:1545-1553.
  • Wehrli N, Legler DF, Finke D, Toellner KM, Loetscher P, Baggiolini M, Mac-Lennan ICM, Acha-Orbea H. 2001. Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur J Immunol 31:609-616.
  • Brandes M, Legler DF, Spoerri B, Schaerli P, Moser B. 2000. Activation-dependent modulation of B lymphocyte migration to chemokines. Int Immunol 12:1285-1292.
  • Arenzana-Seisdedos F, Amara A, Thomas D, Virelizier JL, Baleux F, Clark-Lewis I, Legler DF, Moser B, Baggiolini M. 1998. β-chemokine MDC and HIV-1 infection. Science 281:487a.
  • Willimann K*, Legler DF*, Loetscher M, Stuber Roos R, Delgado MB, Clark-Lewis I, Baggiolini M, Moser B. 1998. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28:2025-2034. * are both considered as first authors
  • Legler DF, Loetscher M, Stuber Roos R, Clark-Lewis I, Baggiolini M, Moser B. 1998. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 187:655-660.
  • Loetscher M, Amara A, Oberlin E, Brass N, Legler DF, Loetscher P, D'Apuzzo M, Meese E, Rousset D, Virelizier JL, Baggiolini M, Arenzana-Seisdedos F, Moser B. 1997. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr Biol 7:652-660.
  • Stuber Roos R, Loetscher M, Legler DF, Clark-Lewis I, Baggiolini M, Moser B. 1997. Identification of CCR8, the receptor for the human CC chemokine I-309. J Biol Chem 272:17251-17254.
  • Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833-835.
  • Legler DF, Loetscher M, Jones SA, Dahinden CA, Arock M, Moser B. 1996. Expression of high- and low-affinity receptors for C3a on the human mast cell line, HMC-1. Eur J Immunol 26:753-758.